Long-term survival benefit after allogeneic hematopoietic cell transplantation in chronic myelomonocytic leukemia

Risk assessment in chronic myelomonocytic leukemia (CMML) is a critical aspect for its management to capture the heterogeneity of this disease.1 In spite of the introduction of several prognostic tools from different groups over the past decade, risk stratification can still be challenging.2 Current collaborative recommendations from the European Hematology Association and the European Leukemia Network suggest to use the CMML-specific scoring system (CPSS) or the MD Anderson prognostic score as such tools if mutational profiling is not available.

Source: Biology of Blood and Marrow Transplantation - October 8, 2020 Category: Hematology Authors: Nico Gagelmann, Rashit Bogdanov, Friedrich St ölzel, Christina Rautenberg, Victoria Panagiota, Heiko Becker, Aleksandar Radujkovic, Thomas Luft, Maximilian Christopeit, Jürgen Finke, Uwe Platzbecker, Markus Ditschkowski, Thomas Schroeder, Michael Koldeh Source Type: research